Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;9(11):1407-25.
doi: 10.1517/14712590903260785.

Treatment of lymphoma with adoptively transferred T cells

Brian G Till  1 , Oliver W Press
Affiliations
Review

Treatment of lymphoma with adoptively transferred T cells

Brian G Till et al. Expert Opin Biol Ther. 2009 Nov.

Abstract

Background: Chemotherapy-resistant lymphomas can be cured with allogeneic hematopoietic cell transplantation, demonstrating the susceptibility of these tumors to T cell mediated immune responses. However, high rates of transplant-related morbidity and mortality limit this approach. Efforts have, therefore, been made to develop alternative T cell based therapies, and there is growing evidence that adoptive therapy with T cells targeted to lymphoma-associated antigens may be a safe and effective new method for treating this group of diseases.

Objective/methods: We review publications on adoptive therapy with ex vivo expanded T cells targeting viral antigens, as well as genetically modified autologous T cells, as strategies for the treatment of lymphoma, with the goal of providing an overview of these approaches.

Results/conclusions: Epstein-Barr virus specific T cell therapy is an effective and safe method of treating Epstein-Barr virus associated lymphomas; however, most lymphoma subtypes do not express EBV antigens. For these diseases, adoptive immunotherapy with genetically modified T cells expressing chimeric T cell receptors targeting lymphoma-associated antigens such as CD19 and CD20 appears to be a promising alternative. Recent innovations including enhanced co-stimulation, exogenous cytokine administration and use of memory T cells promise to overcome many of the limitations and pitfalls initially encountered with this approach.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic comparison of an immunoglobulin, a cTCR molecule, and an endogenous TCR complex. Structural similarity between the immunoglobulin and TCR provided the rationale for developing a chimeric T cell receptor (cTCR), a dimeric fusion protein between an Ab single chain variable fragment (scFv), an extracellular spacer, a transmembrane domain, and an intracellular signaling domain containing one or more immunoreceptor tyrosine-based activation motifs (ITAM).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–73. ** Established that allogeneic marrow grafts confer a graft-versus-leukemia effect.

    1. Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 1999;50:369–86. - PubMed
    1. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008;111:5530–6. - PMC - PubMed
    1. Sorror ML, Storer B, Sandmaier BM, et al. Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Blood. 2008;112 Abstract 2147.
    1. Bishop MR, Dean RM, Steinberg SM, et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol. 2008;19:1935–40. - PMC - PubMed

Publication types

Substances